AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02098590 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: malaria challenge infection, P. falciparum NF166.C8
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
Study NCT02098590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum NF166.C8
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
Study NCT02098590 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: malaria challenge infection, P. falciparum NF54
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
Study NCT02098590 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: atovaquone/proguanil
Description: All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
Study NCT02098590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atovaquone/proguanil
Description: All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
Study NCT03465878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered via SC injection
Study NCT02267460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Investigator Modeling
Study NCT02201784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Comparison of Equipotent doses
Study NCT02201784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Comparison of equipotent doses
Study NCT03685214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Description: we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
Study NCT03465878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered via SC injection
Study NCT03685214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactated Ringer's solution
Description: we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
Study NCT01868347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment
Description: preemptive PEEP before pneumoperitoneum and trendelenburg
Study NCT04122235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LETSGO follow-up
Description: Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
Study NCT04014452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
Study NCT00542581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Acrysof toric SN60T3 IOL
Description: Intraocular Lens
Study NCT01868347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: PEEP after pneumoperitoneum and trendelenburg
Study NCT04174625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Omega3-FA
Description: Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
Study NCT03188991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
Study NCT01184274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~1. (starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~2. - 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~3. - 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
Study NCT01728194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20 mg target dose for 12 weeks
Study NCT01728194 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Structural and functional MRI of the brain for research purposes.
Study NCT01728194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Structural and functional MRI of the brain for research purposes.
Study NCT04864197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: prf membrane placement over implant site for gingival thickening
Study NCT02581501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAX - Gemcitabine, Abraxane and Xeloda
Description: GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
Study NCT01097057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01097057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01097057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT01097057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT01097057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Given through catheter
Study NCT01097057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC
Study NCT01097057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02683031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ca2+ ionophore
Description: Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
Study NCT00207363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin, Peg interferon alfa 2b
Description: Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
Study NCT00207363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction therapy
Description: Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
Study NCT03682926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-stimulation
Description: Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
Study NCT03682926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electro-stimulation
Description: Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
Study NCT02312414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Canitine
Description: Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
Study NCT00361504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
Study NCT00361504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol (CG5503) ER
Description: Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
Study NCT04613804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle.
Study NCT02256956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25 mg / day for 10 days
Study NCT01369732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
Study NCT01369732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
Study NCT03851432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janagliflozin plus metformin
Description: Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
Study NCT03851432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janagliflozin plus metformin
Description: Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
Study NCT03851432 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus metformin
Description: Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
Study NCT04138043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
Study NCT04138043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be available as SC injection 150 mg/mL.
Study NCT03282500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
Study NCT01892124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/Cognitive Behavioral-based Therapy
Study NCT01770015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biological sampling
Description: cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
Study NCT01770015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sampling blood
Description: HLA DR antigen, cytokines (IL 6 and 10), B-glucan
Study NCT01770015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal aspiration
Description: fungi and bacteria endotracheal aspiration
Study NCT04166617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: conventional physcial therapy rehabilitation for the upper limb
Study NCT04166617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leap motion plus conventional therapya
Description: leap motion plus conventional physcial therapy rehabilitation for the upper limb
Study NCT01500902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EndoPAT testing (non invasive device)
Description: Using the EndoPAT device, we will assess endothelial function.
Study NCT01500902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WatchPAT testing (non-invasive device)
Description: Using the WATCHPAT device we will assess sleep apnea.
Study NCT03170193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 529
Description: Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
Study NCT03170193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses of matching placebo by SC or IV injection
Study NCT01700153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic-assisted therapy
Description: This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
Study NCT01700153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical therapy
Description: conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
Study NCT01700153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical therapy
Description: conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
Study NCT03273309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vibratory Perineal Stimulus
Description: Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
Study NCT02256956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Placebo 1 mg / day for 10 days
Study NCT03273309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal Electrical Stimulation
Description: The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
Study NCT01301859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIP
Description: Treatment visits as usual with MD
Study NCT01301859 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TIP
Description: Treatment visits as usual with MD
Study NCT00238238 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV
Study NCT00238238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00238238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT02861638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Video of the exercises
Study NCT02861638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: video of nature scenes
Study NCT02861638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Mobilization, exercises and transfer practice.
Study NCT02861638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Mobilization, exercises and transfer practice.
Study NCT02727920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy drink
Study NCT02727920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo drink
Study NCT03673163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
Study NCT03673163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
Study NCT03413059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Thoracic Epidural morphine
Study NCT03413059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: thoracic epidural triamcinolone acetonide
Study NCT01818063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT04014452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
Study NCT03171012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower limbs CRT
Description: cycle ergometer for lower limbs
Study NCT03171012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limbs CRT
Description: cycle ergometer for lower limbs
Study NCT03171012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limbs CRT
Description: cycle ergometer for upper limbs
Study NCT03171012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper limbs CRT
Description: cycle ergometer for upper limbs
Study NCT03171012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
Study NCT03171012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiration
Description: respiration
Study NCT01910428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in RBC
Description: * 50 IU/kg IV~* 100 IU/kg IV~* 150 IU/kg IV~* 200 IU/kg IV
Study NCT02893085 — intervention group
Intervention type: BIOLOGICAL
Intervention: bile sample analysis
Description: tumor mutation profile tumor genotype
Study NCT02893085 — intervention group
Intervention type: BIOLOGICAL
Intervention: biochemical markers, VEGF and MMPs, in bile samples
Study NCT02054338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine+Gemcitabine
Description: Vinflunine 320 mg/m² IV on day 1 and.Gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks
Study NCT02054338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel+Gemcitabine
Description: paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
Study NCT01342510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Sulfate
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
Study NCT00556244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peeling
Description: ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
Study NCT01342510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
Study NCT01818063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01818063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT01818063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01818063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT04225793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eziklen®
Description: The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure.
Study NCT04225793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep
Description: The Moviprep® solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Moviprep® solution should be completed at least 2 hours and no later than 4 hours before the procedure.
Study NCT01085292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d